Market Overview

Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison, Competitive Landscape - Global Forecasts to 2022 - ResearchAndMarkets.com

Share:

The "Breast
Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User,
Investments, Market Dynamics, Platform Comparison, Competitive Landscape
- Global Forecasts to 2022"
report has been added to ResearchAndMarkets.com's
offering.

The global breast cancer liquid biopsy market is estimated to grow at a
CAGR of 23.1% from 2017 to 2022, from USD 145.4 million in 2017 to reach
USD 411.1 million by 2022.

Increasing prevalence of breast cancer, increasing preference for
noninvasive procedures, and availability of funding for liquid biopsy
R&D are some of the key factors driving the growth of the market.
Unclear regulatory and reimbursement scenario is one of the major
challenges faced by the market.

Based on circulating biomarkers, the market is categorized into
circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular
vesicles (EVs), and other circulating biomarkers. The cfDNA segment is
the fastest-growing segment in the circulating biomarkers market during
the forecast period. This is due to the growing interest in cfDNA
research from biofluids such as the blood of cancer patients as a means
of disease diagnosis and therapeutic monitoring.

Based on end user, the market is categorized into reference
laboratories, hospitals and physician laboratories, and other end users.
The reference laboratories segment is the largest end-user segment of
the global breast cancer liquid biopsy market. Reference laboratories
are well-equipped large laboratories with facilities for genomic testing
of samples, thus receiving major share of samples from hospitals and
private practitioners.

Key Topics Covered:

1 Liquid Biopsy: Market at A Glance

2 Liquid Biopsy: Circulating Biomarkers

3 Liquid Biopsy: Market Overview

4 Major Investments & Initiatives

5 Breast Cancer Liquid Biopsy Market

6 Liquid Biopsy Market: Competitive Landscape

7 Appendix

Companies Mentioned

  • QIAGEN N.V.
  • Roche Diagnostics
  • Illumina, Inc.
  • Bio-Rad Laboratories
  • Myriad Genetics
  • Menarini Silicon Biosystems
  • Cynvenio Biosystems, Inc.
  • Genomic Health, Inc.
  • Thermo Fisher Scientific Inc.
  • Fluxion Biosciences, Inc.
  • Biodesix, Inc.
  • Guardant Health, Inc.
  • Isogen Life Science B.V.

For more information about this report visit https://www.researchandmarkets.com/research/w66bz9/breast_cancer?w=4

View Comments and Join the Discussion!